Search bioRxiv⌕ Search

Biology subjects

Tuzun, E.

Publications and source records attributed to Tuzun, E..

2 recordsLinked to original sources

A Novel Mouse Model Demonstrates In Vivo Replenishment of Central Nervous System Pericytes After Successful Acute Ablation

Central nervous system (CNS) pericytes play crucial roles in vascular development and blood-brain barrier maturation during prenatal development, as well as in regulating cerebral blood flow in adults. They have also been implicated in the pathogenesis of numerous neurological disorders. However, the behavior of pericytes in the adult brain after injury remains poorly understood, partly due to limitations in existing pericyte ablation models. To investigate pericyte responses following acute ablation, we developed a tamoxifen-inducible pericyte ablation model by crossing PDGFR{beta}-P2A-CreERT2 and Rosa26-DTA176 transgenic mouse lines. Using this model, we studied the effects of different tamoxifen doses and conducted histological examinations 15 and 60 days post-injection to assess both short- and long-term impacts of pericyte ablation. Our results demonstrate that a low dose of tamoxifen effectively ablates CNS pericytes in mice without reducing survival or causing significant systemic side effects, such as weight loss. Additionally, we found that the extent of pericyte depletion varies between the cortex and the spinal cords gray and white matter regions. Importantly, both pericyte coverage and numbers increased in the weeks following acute ablation, indicating the regenerative capacity of CNS pericytes in vivo. This model offers a valuable tool for future studies on the role of pericytes in neurological disorders, overcoming the limitations of constitutive pericyte ablation models.

neuroscience↗

Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy

Immunity against cancer cells is at the forefront of fight against highly malignant tumors like glioblastomas (GBM). Autoantibodies and their autoantigen cooperators are one of the promising biomarkers linked to the immune responses and have been reported as having an initiative or prognostic role for certain types of paraneoplastic disorders. Nevertheless, immunoreactivity against antigens expressed in GBM are poorly studied. To date, autoantibodies were identified by pursuing targeted approaches. By contrast, in this study, we collected human GBM tissue and sera samples and by applying proteomics analysis, we determined autoantigen candidates for GBM. Subsequent immunohistochemistry and immunoprecipitation experiments revealed that a solute carrier; SLC3A2 is widely overexpressed in GBMs and therefore, immunoreactivity against SLC3A2 is present in high grade GBM, and SLC3A2 expression is altered in GBMs. No antibody interaction was detected in SLC3A2 expressors of low grade gliomas. Furthermore, autoantibody presence was correlated with prolonged survival of GBM patients. Taken together, for the first time, we reported that the SLC3A2 immunoreaction exists in high grade gliomas with a distinct GBM profile. In conclusion, our findings may open up new avenues for our understanding of glioma prognosis in the context of autoimmunity. This may eventually lead to diagnostic and therapeutic inventions that can be utilized for prevention of the disease progression.

immunology↗